Valvular & structural heart diseaseCohort study
Applying the 2025 ESC/EACTS Recommendations for the Treatment of Severe Tricuspid Regurgitation to Real-World Practice
- Registry-based cohort study
- multicentre registry (EuroTR)
Authors' conclusion
T-TEER may provide symptomatic benefit in selected high-risk patients with severe LVD, RVD, or pcPH.
Study context
- Population
- Patients undergoing tricuspid valve transcatheter edge-to-edge repair (T-TEER) in the European Registry of Transcatheter Repair for Tricuspid Regurgitation
- Participants
- 1,626 T-TEER patients
- Exposure
- Optimal medical therapy (OMT) candidates vs transcatheter tricuspid valve interventions (TTVI) appropriate undergoing T-TEER
- OMT candidatesn = 213
- Outcome
- NYHA functional class improvement and survival free from HF hospitalization
- Follow-up
- 2 years
Main finding
As reported in the abstract
HF hospitalization-free survival and ≥1-class NYHA improvement
HF hospitalization-free survival
P < 0.001
≥1 NYHA class improvement
P = 0.68
Observational data: associations, not effects.
Further findings
1-year HF hospitalization-free survival, by criterion (severe vs not)
- Severe LV dysfunction
- 54.6% vs 72.9% [P < 0.001]
- Severe RV dysfunction
- 59.0% vs 73.2% [P = 0.003]
- Precapillary pulmonary hypertension
- 56.2% vs 73.4% [P = 0.021]
- median survival follow-up 446 days [Q1-Q3: 192-805 days]
≥1 NYHA class improvement, by criterion (severe vs not)
- Severe LV dysfunction
- 51.1% vs 59.4% [P = 0.25]
- Severe RV dysfunction
- 59.7% vs 59.0% [P = 0.90]
- Precapillary pulmonary hypertension
- 51.3% vs 59.4% [P = 0.31]
Original publication
Applying the 2025 ESC/EACTS Recommendations for the Treatment of Severe Tricuspid Regurgitation to Real-World Practice. JACC Cardiovasc Interv. Published 13 April 2026. doi:10.1016/j.jcin.2026.02.024
Summarised from the published abstract; every number is checked against it